Embecta Corp.
Financials
Valuation Metrics
Embecta Corp.'s Market Cap is $352M. At end of 2025 it was $683M. Ranked #2856 of 3,118 in US market (top 92%), #1276 of 1,474 on NASDAQ (top 87%), #180 of 203 in Health Care Equipment & Services (top 89%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $352M | US#2,856/3,118 Sec#180/203 |
| Revenue | $1.02B | US#1,853/3,118 Sec#115/203 |
| Net Income | $88M | US#1,669/3,118 Sec#87/203 |
| Total Assets | $1.27B | US#2,347/3,118 Sec#121/203 |
| Net Assets | $-613M | US#3,017/3,118 Sec#200/203 |
| Employees | 1,850 | US#1,714/3,118 Sec#117/203 |
| Value | ||
| P/E | 4.02x | US#36/3,118 Sec#1/203 |
| PEG | 0.72x | US#740/3,118 Sec#34/203 |
| P/S | 0.35x | US#207/3,118 Sec#19/203 |
| EV/EBITDA | 5.99x | US#279/3,118 Sec#6/203 |
| FCF Yield | 46.78% | US#44/3,118 Sec#2/203 |
| Profitability | ||
| ROA | 6.92% | US#806/3,118 Sec#51/203 |
| Op. Margin | 24.85% | US#679/3,118 Sec#18/203 |
| Revenue Growth | -7.60% | US#2,507/3,118 Sec#189/203 |
| Earnings Growth | 5.55% | US#1,174/3,118 Sec#67/203 |
| Financial Health | ||
| Total Debt | $1.50B | US#1,307/3,118 Sec#66/203 |
| FCF | $165M | US#1,482/3,118 Sec#87/203 |
| Cash | $215M | US#1,682/3,118 Sec#100/203 |
| Current Ratio | 1.68x | US#1,465/3,118 Sec#132/203 |
| Net Debt/EBITDA | 4.70x | US#1,966/3,118 Sec#128/203 |
| Dividend | ||
| Div. Yield | 7.73% | US#138/3,118 Sec#2/203 |
| Div. Growth | 1.68% | US#1,087/3,118 Sec#38/203 |
| Payout Ratio | 25.42% | US#8/3,118 Sec#2/203 |
| Performance | ||
| 1Y Return | -52.16% | US#2,904/3,118 Sec#190/203 |
| 1M Return | 9.91% | US#747/3,118 Sec#59/203 |
| From 52W High | -57.20% | US#2,776/3,118 Sec#186/203 |
| 1Y MDD | -79.64% | US#3,036/3,118 Sec#198/203 |
| Trading | ||
| Volume | 537,152 shares | US#1,891/3,118 Sec#133/203 |
| Trading Value | $3M | US#2,700/3,118 Sec#175/203 |
| Per Share | ||
| EPS | $1.54 | US#1,488/3,118 Sec#76/203 |
| BPS | $-10.81 | US—/3,118 Sec—/203 |
Company Info
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.